{"id":2172,"date":"2011-02-01T12:06:00","date_gmt":"2011-02-01T11:06:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2011\/meningitis-als-unerwuenschte-arzneimittelwirkung"},"modified":"2022-03-17T14:12:03","modified_gmt":"2022-03-17T13:12:03","slug":"meningitis-als-unerwuenschte-arzneimittelwirkung","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2011\/meningitis-als-unerwuenschte-arzneimittelwirkung","title":{"rendered":"Meningitis als unerw\u00fcnschte Arzneimittelwirkung"},"content":{"rendered":"<p>Die US Food and Drug Administration (FDA) ordnete im August 2010 an, dass in den USA zuk\u00fcnftig in allen Beipackzetteln des als Antikonvulsivum und zur Behandlung bipolarer Erkrankungen zugelassenen Lamotrigin (Lamictal\u00ae) vor einer aseptischen Meningitis (Drug induced aseptic meningitis = DIAM) als UAW gewarnt werden muss (1). Dieser Entscheidung liegen 40 Berichte aus den vergangenen [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Die US Food and Drug Administration (FDA) ordnete im August 2010 an, dass in den USA zuk\u00fcnftig in allen Beipackzetteln des als Antikonvulsivum und zur Behandlung bipolarer Erkrankungen zugelassenen Lamotrigin (Lamictal\u00ae) vor einer aseptischen Meningitis (Drug induced aseptic meningitis = DIAM) als UAW gewarnt werden muss (1). Dieser Entscheidung liegen 40 Berichte aus den vergangenen [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[619,22,255,239,1359,1692,1693,1355,1360,611,502,150,626,627,646,631,635,237,257,1506,276,680,256,564,562,563,565,4363,673,1858,2585,4362,1678,254,253,1350],"class_list":["post-2172","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-allopurinol","tag-amoxicillin","tag-arzneimittel","tag-azathioprin","tag-cetuximab","tag-co-trimoxazol","tag-cotrimoxazol","tag-cox-2-hemmer","tag-coxibe","tag-diclofenac","tag-ibuprofen","tag-immunglobuline","tag-indometacin","tag-indomethacin","tag-inh","tag-isoniazid","tag-ketoprofen","tag-lamotrigin","tag-medikamente","tag-meningitis","tag-methotrexat","tag-naproxen","tag-nebenwirkungen","tag-nichtsteroidale-antiphlogistika","tag-nichtsteroidale-antirheumatika","tag-nsaid","tag-nsar","tag-okt3-monoklonaler-ak","tag-piroxicam","tag-rofecoxib","tag-sulindac","tag-tolmetin","tag-trimethoprim-sulfamethoxazol","tag-uaw","tag-unerwuenschte-arzneimittelwirkungen","tag-zyklooxygenase-2-hemmer"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2172","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2172"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2172\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2172"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2172"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2172"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}